At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 108 enrolled
Drug / intervention
NVN1000 8% Gel +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts
In Brief
A Phase 2 clinical trial evaluating NVN1000 8% Gel, NVN1000 16%, and 2 other interventions for Genital Warts and Perianal Warts. Completed, enrolled 108 participants across 15 sites.
Detailed Summary
A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects with External Genital Warts and Perianal Warts
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGenital Warts, Perianal Warts
CountriesUnited States
CollaboratorsPPD Development, LP
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartJun 2015
Primary CompletionOct 2016
Study CompletionOct 2016
TodayJul 2026
First PostedJun 3, 2015
Enrollment StartJun 12, 2015
Primary CompletionOct 1, 2016
Study CompletionOct 17, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.1 years ago
Interventions
NVN1000 8% Geldrug
once and twice daily
NVN1000 16%drug
once daily
Vehicledrug
placebo comparator
NVN1000 24%drug
once daily